MATH2WARD
From math to ward: mathematical models in the doctor's hand
| Coordinatore | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE
Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie. |
| Nazionalità Coordinatore | Switzerland [CH] |
| Totale costo | 167˙983 € |
| EC contributo | 149˙785 € |
| Programma | FP7-IDEAS-ERC
Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | ERC-2012-PoC |
| Funding Scheme | CSA-SA(POC) |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-05-01 - 2014-04-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
MOXOFF SRL-SPIN OFF DEL POLITECNICODI MILANO
Organization address
address: VIALE VITTORIO VENETO 2/A contact info |
IT (MILANO) | beneficiary | 64˙078.00 |
| 2 |
WARRANT GROUP S.R.L.
Organization address
address: CORSO MAZZINI 11 contact info |
IT (CORREGGIO (RE)) | beneficiary | 46˙117.00 |
| 3 |
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE
Organization address
address: BATIMENT CE 3316 STATION 1 contact info |
CH (LAUSANNE) | hostInstitution | 39˙590.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The MATH2WARD PoC intends to investigate the commercial feasibility of a light smart platform for everyday clinical practice which, upon receiving and elaborating a patient’s characteristics from classical medical equipment, can provide in real-time quantitative output based on numerical simulation, improving clinicians’ knowledge and driving their decisions. The mathematical engine can run algorithms very quickly and provide elaborations of multiple and meaningful inputs. The domain of intervention is that of cardiovascular diseases and the final users are cardiologists, cardiovascular surgeons or, more generally, clinicians dealing with subjects affected by cardiovascular pathologies. The potential benefits include: helping clinicians make decisions on diagnosis - i.e. in detecting surgery necessity; improving the quality of communication (clinician-clinician and clinician-patients) thanks to clear and meaningful visualisations; enhancing knowledge management. Thus the products derived from the platform could speed up and ameliorate the necessary time and expenses for diagnosis, therefore allowing to reduce the costs of hospitalisation and treatments. The preliminary analysis shows that the products deriving from the platform (a SW and a device with integrated SW) could have a significant impact on the industrial market. The PoC activities will further investigate the suitable commercialisation processes (i.e. direct industrialization or licensing for outsourced development, direct commercialization, and/or joint venture with clinical devices manufacturers). It will further define innovative and distinctive characteristics of the products through technology intelligence, after validation (testing in clinical environment and assessment by stakeholders). It will better define an IPR protection strategy (i.e. copyright for SW and patent for the device), and allow agreements with industrial/financial partners for the products industrialization and commercialization.'